Study guide
Section 10.3: Identifying Adverse Drug Reactions & Complications
AANP Family Nurse Practitioner Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical History & Lifespan Assessment
Section 1.1: Lifespan Health History: Newborn through Geriatric Care Section 1.2: Social Drivers of Health & Cultural Competence Section 1.3: Risk Assessment and Stratification
2 Chapter 2: Physical Examination & Physical Assessment
Section 2.1: Developmental Milestones & Pediatric Exams Section 2.2: Advanced Adult & Geriatric Physical Exams Section 2.3: Identifying Clinical Red Flags & Abuse/Neglect
3 Chapter 3: Diagnostic Screening, Testing, & Interpretation
Section 3.1: Primary Care Screening Guidelines Section 3.2: Interpreting Diagnostic Laboratory Panels Section 3.3: Ordering & Interpreting Imaging Studies Section 3.4: Electrocardiology & Pulmonary Function Tests
4 Chapter 4: Differential Diagnosis of Cardio-Respiratory & Endocrine Disorders
Section 4.1: Differentials in Cardiovascular Conditions Section 4.2: Differentials in Respiratory Conditions Section 4.3: Differentials in Endocrine and Metabolic Disorders
5 Chapter 5: Differential Diagnosis of GI, GU, & Reproductive Disorders
5.1 Differentials in Gastrointestinal Conditions 5.2 Differentials in Genitourinary and Renal Conditions 5.3 Differentials in Reproductive and Women's Health
6 Chapter 6: Differential Diagnosis of Neuro, MSK, Derm, & Psych Disorders
Section 6.1: Differentials in Musculoskeletal and Neurological Disorders Section 6.2: Differentials in Dermatological and Psychiatric Conditions
7 Chapter 7: Pharmacotherapeutic Principles & Prescribing Guidelines
Advanced Pharmacotherapeutic Principles Safe Prescribing in Special Populations Prescription Writing, Regulation, and Controlled Substances
8 Chapter 8: Evidence-Based Management of Common Primary Care Disorders
Section 8.1: Pharmacological Treatment Plans Section 8.2: Non-Pharmacological & Integrative Management Section 8.3: Referrals, Consultations, and Interprofessional Collaboration
9 Chapter 9: Health Promotion, Education, & Care Coordination
Section 9.1: Patient and Caregiver Education Section 9.2: Ethics, Consent, & Legal Scope in Treatment Planning
10 Chapter 10: Clinical Outcome Evaluation & Treatment Modification
Section 10.1: Monitoring Treatment Efficacy & Patient Adherence Section 10.2: Lab & Diagnostic Follow-Up in Care Monitoring Section 10.3: Identifying Adverse Drug Reactions & Complications Section 10.4: Criteria for Care Plan Modification & Escalation
Section 10.3: Identifying Adverse Drug Reactions & Complications
Key Takeaways Explain This Topic AI
The AGS Beers Criteria lists potentially inappropriate medications for older adults, including benzodiazepines, first-generation antihistamines, and NSAIDs.
Drug-Induced Liver Injury (DILI) is classified into hepatocellular or cholestatic patterns; drug discontinuation is required if transaminases exceed 3 times the upper limit of normal with symptoms.
Drug-Induced Kidney Injury (DIKI) can occur hemodynamically (NSAIDs via afferent constriction, ACEIs via efferent dilation) or immunologically (AIN via penicillins, sulfonamides, and PPIs).
Severe cutaneous hypersensitivity reactions like Stevens-Johnson Syndrome (SJS) present with flaccid blisters and a positive Nikolsky sign, requiring immediate hospital transfer.
Last updated: July 2026
Section 10.3: Identifying Adverse Drug Reactions & Complications
The family nurse practitioner (FNP) must be highly vigilant in detecting, managing, and preventing adverse drug reactions (ADRs), medication toxicities, and drug-induced organ damage. Adverse drug events contribute significantly to emergency department visits and hospitalizations, particularly in vulnerable populations such as geriatric patients. Evaluating for ADRs requires an understanding of clinical pharmacology, pathophysiology, and risk-stratification tools like the Beers Criteria.
The Beers Criteria and High-Risk Medications in Geriatrics
The American Geriatrics Society (AGS) Beers Criteria lists medications that are potentially inappropriate for older adults (aged 65 and older) because the risk of adverse events outweighs the clinical benefit. Key drug classes and their associated risks include:
First-Generation Antihistamines (e.g., Diphenhydramine, Hydroxyzine): These agents possess potent anticholinergic properties. In older adults, they cause a significant "anticholinergic burden," leading to confusion, delirium, dry mouth, blurred vision, urinary retention, and constipation. They also increase the risk of falls due to sedation.
Benzodiazepines (e.g., Diazepam, Alprazolam, Temazepam): Older adults have reduced hepatic clearance and increased central nervous system sensitivity. They are associated with cognitive impairment, delirium, falls, fractures, and motor vehicle accidents.
Tricyclic Antidepressants (e.g., Amitriptyline): Highly anticholinergic, sedating, and cause orthostatic hypotension, which increases fall risk. They can also cause cardiac conduction abnormalities.
Long-Acting Sulfonylureas (e.g., Glyburide, Glimepiride): These agents stimulate insulin secretion regardless of blood glucose levels and have prolonged half-lives in older adults, leading to severe, prolonged, and sometimes fatal hypoglycemia.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs - e.g., Ibuprofen, Naproxen): Associated with a high risk of gastrointestinal bleeding, peptic ulcer disease, fluid retention, worsening of heart failure, and acute kidney injury.
Drug-Induced Liver Injury (DILI)
The liver is the primary site of drug metabolism, making it highly susceptible to toxic insults. Drug-Induced Liver Injury (DILI) is categorized pathologically:
Hepatocellular Injury: Characterized by a disproportionate rise in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) compared to alkaline phosphatase (ALP). Key offenders include Acetaminophen (accidental overdose leads to accumulation of the toxic metabolite N-acetyl-p-benzoquinone imine [NAPQI], which depletes glutathione; managed with N-acetylcysteine ), Amiodarone (causes direct hepatotoxicity, thyroid dysfunction, and pulmonary fibrosis), Isoniazid , and Methotrexate .
Cholestatic Injury: Characterized by a disproportionate rise in ALP and bilirubin compared to ALT/AST. Common causes include clavulanate (in amoxicillin-clavulanate) and erythromycin.
Clinical Evaluation: FNPs should suspect DILI if ALT or AST levels rise greater than 3 times the upper limit of normal (ULN) in the presence of symptoms (such as jaundice, dark urine, or right upper quadrant pain) or greater than 5 times the ULN in an asymptomatic patient. Immediate discontinuation of the offending agent is required.
Drug-Induced Kidney Injury (DIKI)
Drug-induced kidney injury is a common cause of acute kidney injury (AKI) in primary care. The primary mechanisms include:
Hemodynamic (Prerenal) AKI:
NSAIDs inhibit renal prostaglandins, which normally maintain renal blood flow by dilating the afferent arteriole. NSAID use results in unopposed afferent vasoconstriction.
ACEIs and ARBs prevent angiotensin II-mediated vasoconstriction of the efferent arteriole, causing efferent vasodilation. Under conditions of hypovolemia, this drops intraglomerular pressure, precipitating AKI.
Acute Tubular Necrosis (ATN): Direct toxic damage to renal tubular cells. Common causes include Aminoglycosides (e.g., gentamicin), Amphotericin B , and intravenous contrast media .
Acute Interstitial Nephritis (AIN): An immunologically mediated hypersensitivity reaction in the renal interstitium. Common triggers include Penicillins , Sulfonamides (e.g., Bactrim), and Proton Pump Inhibitors (PPIs) . AIN often presents with sterile pyuria, eosinophils in the urine, fever, and a maculopapular rash.
Severe Cutaneous Hypersensitivity Reactions
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening, immunologically mediated hypersensitivity reactions characterized by epidermal necrosis and mucosal desquamation.
Offending Medications: Allopurinol, sulfamethoxazole-trimethoprim (Bactrim), carbamazepine, phenytoin, and lamotrigine.
Clinical Indicators: A painful, erythematous or purpuric rash that progresses to flaccid blisters. A positive Nikolsky sign (where gentle lateral pressure on the skin causes the epidermis to detach from the dermis) is a clinical diagnostic marker. SJS involves <10% of total body surface area, while TEN involves >30% skin detachment. Immediate discontinuation of the drug and transfer to a burn unit is mandatory.
Toxic Agent Type of Organ Injury / Toxicity Key Clinical & Lab Indicators Immediate Management / Antidote
Acetaminophen Hepatotoxicity (Hepatocellular DILI) Elevated ALT/AST (>1,000 U/L in severe cases), jaundice, right upper quadrant pain N-acetylcysteine (NAC) (replenishes glutathione stores)
Digoxin Cardiotoxicity / Neurotoxicity Nausea, vomiting, bradycardia, visual changes (yellow-green halos, xanthopsia), hyperkalemia Stop drug; monitor ECG; administer Digoxin Immune Fab (Digibind)
Warfarin Hematologic toxicity (Bleeding) Asymptomatic elevated INR; bruising; hematuria; active hemorrhage Hold warfarin; administer Vitamin K (phytonadione) or Prothrombin Complex Concentrate (PCC)
NSAIDs Nephrotoxicity (DIKI via afferent vasoconstriction) Elevated creatinine, decreased eGFR, hyperkalemia, peripheral edema Discontinue drug; evaluate volume status; switch to acetaminophen if appropriate
Bactrim / Allopurinol Severe Cutaneous Hypersensitivity Painful rash, mucosal ulcers, positive Nikolsky sign, fever Immediate discontinuation; emergency transfer to burn center
Clinical Traps for the FNP Exam
Important
Exam Alert: The Beers Criteria explicitly identifies diphenhydramine as inappropriate for use as a sleep aid in older adults. If an elderly patient presents with insomnia, do not recommend diphenhydramine or other over-the-counter PM products. Instead, recommend non-pharmacological sleep hygiene, or low-dose melatonin if necessary.
Warning
Clinical Trap: Do not confuse the mechanism of kidney injury between NSAIDs and ACE inhibitors. NSAIDs constrict the afferent arteriole (blood flow in), while ACE inhibitors dilate the efferent arteriole (blood flow out). Combining these drugs with a diuretic creates the "triple whammy," which drastically reduces GFR and causes severe AKI.
Worked Clinical Scenario
Case: A 76-year-old female is brought to the clinic by her daughter due to progressive confusion, dry mouth, and two near-fall episodes over the past three days. Her medical history includes osteoarthritis and mild cognitive impairment. Her medication list includes acetaminophen 500 mg as needed for pain. Upon further questioning, the daughter reveals she bought an over-the-counter sleep aid containing diphenhydramine 50 mg to help her mother sleep at night.
FNP Clinical Reasoning:
Analyze Clinical Presentation: The patient presents with symptoms characteristic of an anticholinergic toxidrome (confusion, dry mouth, visual changes, gait instability leading to near-falls).
Identify the Offending Agent: Diphenhydramine is a first-generation antihistamine with high anticholinergic activity. It is listed on the Beers Criteria as potentially inappropriate for older adults due to these exact risks, which are amplified in patients with pre-existing cognitive impairment.
Formulate the Plan: Instruct the daughter to stop administering the sleep aid immediately. Perform a physical exam (including orthostatic vitals, neurological assessment, and check for urinary retention). Educate the patient and daughter on non-pharmacological sleep hygiene strategies. Schedule a safety check-in call within 48 hours to ensure the patient's confusion has resolved.